Re-Evaluation of Need and Tapering of Omalizumab in Chronic Idiopathic Urticaria

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.926
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Omalizumab for Chronic Idiopathic Urticaria: Potential to Taper Dose and Frequency?

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Omalizumab vs. Placebo in the Management of Chronic Idiopathic Urticaria: A Systematic Review

World Allergy Organization Journal
ImmunologyPulmonaryAllergyRespiratory Medicine
2014English

Omalizumab in Chronic Urticaria: A Comprehensive Review

Turkderm Deri Hastaliklari ve Frengi Arsivi
DermatologyInfectious Diseases
2018English

Omalizumab Response in Patients With Chronic Idiopathic Urticaria: Insights From the XTEND-CIU Study

Journal of the American Academy of Dermatology
Dermatology
2018English

Efficacy of Omalizumab in Treatment-Resistant Chronic Spontaneous Urticaria

Asim, Allerji, Immunoloji
Respiratory MedicinePulmonaryAllergyImmunology
2018English

Omalizumab Treatment in Patients With Chronic Spontaneous Urticaria

Bőrgyógyászati és Venerológiai Szemle
2015English

Effectiveness of Omalizumab in Adolescent and Adult Patients With Chronic Idiopathic/Spontaneous Urticaria: A Systematic Review of “Real-World” Evidence

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2018English

Increased Epidermal Filaggrin in Chronic Idiopathic Urticaria Is Associated With Severity of Urticaria

Annals of Allergy, Asthma and Immunology
Respiratory MedicinePulmonaryAllergyImmunology
2014English

Effects of Omalizumab on Chronic Urticaria Not Responding to Recommended Therapy

Allergy, Asthma and Clinical Immunology
ImmunologyPulmonaryAllergyRespiratory Medicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy